BioAffinity gets U.S. patent for novel broad spectrum cancer therapies

BioAffinity Technologies (BIAF) announced the U.S. Patent and Trademark Office has issued a new patent covering a novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The patent, “Compositions and Methods for Treating Cancer”, provides for use of the therapeutic approach with lung, breast, prostate, brain, and skin cancers. Research has begun toward developing a topical treatment for skin cancers.